Next Article in Journal
Gypenoside Inhibits Bovine Viral Diarrhea Virus Replication by Interfering with Viral Attachment and Internalization and Activating Apoptosis of Infected Cells
Next Article in Special Issue
Impact of Phage CDHS-1 on the Transcription, Physiology and Pathogenicity of a Clostridioides difficile Ribotype 027 Strain, R20291
Previous Article in Journal
Embryonic Stage of Congenital Zika Virus Infection Determines Fetal and Postnatal Outcomes in Mice
Previous Article in Special Issue
Examining the Effects of an Anti-Salmonella Bacteriophage Preparation, BAFASAL®, on Ex-Vivo Human Gut Microbiome Composition and Function Using a Multi-Omics Approach
 
 
Review

Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections

1
Occupation, Environment and Safety, School of Population Health, Curtin University, Perth 6845, Australia
2
Wal-yan Respiratory Research Centre, Telethon Kids Institute, Perth 6009, Australia
3
Advanced Drug Delivery Group, Sydney Pharmacy School, University of Sydney, Camperdown 2006, Australia
4
Department of Respiratory and Sleep Medicine, Perth Children’s Hospital, Perth 6009, Australia
5
Centre for Cell Therapy and Regenerative Medicine, School of Medicine and Pharmacology, Harry Perkins Institute of Medical Research, The University of Western Australia, Nedlands 6009, Australia
*
Author to whom correspondence should be addressed.
Academic Editors: Zuzanna Drulis-Kawa and Daria Augustyniak
Viruses 2021, 13(9), 1809; https://doi.org/10.3390/v13091809
Received: 13 July 2021 / Revised: 8 September 2021 / Accepted: 9 September 2021 / Published: 11 September 2021
(This article belongs to the Special Issue Phage-Bacteria Interplay in Health and Disease)
The emergence of multi-drug resistant (MDR) bacteria is recognised today as one of the greatest challenges to public health. As traditional antimicrobials are becoming ineffective and research into new antibiotics is diminishing, a number of alternative treatments for MDR bacteria have been receiving greater attention. Bacteriophage therapies are being revisited and present a promising opportunity to reduce the burden of bacterial infection in this post-antibiotic era. This review focuses on the current evidence supporting bacteriophage therapy against prevalent or emerging multi-drug resistant bacterial pathogens in respiratory medicine and the challenges ahead in preclinical data generation. Starting with efforts to improve delivery of bacteriophages to the lung surface, the current developments in animal models for relevant efficacy data on respiratory infections are discussed before finishing with a summary of findings from the select human trials performed to date. View Full-Text
Keywords: multi-drug resistance; bacteriophage; respiratory; infectious disease multi-drug resistance; bacteriophage; respiratory; infectious disease
Show Figures

Figure 1

MDPI and ACS Style

Iszatt, J.J.; Larcombe, A.N.; Chan, H.-K.; Stick, S.M.; Garratt, L.W.; Kicic, A. Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections. Viruses 2021, 13, 1809. https://doi.org/10.3390/v13091809

AMA Style

Iszatt JJ, Larcombe AN, Chan H-K, Stick SM, Garratt LW, Kicic A. Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections. Viruses. 2021; 13(9):1809. https://doi.org/10.3390/v13091809

Chicago/Turabian Style

Iszatt, Joshua J., Alexander N. Larcombe, Hak-Kim Chan, Stephen M. Stick, Luke W. Garratt, and Anthony Kicic. 2021. "Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections" Viruses 13, no. 9: 1809. https://doi.org/10.3390/v13091809

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop